L-Isoleucine
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | L-Isoleucine |
|---|---|
| Chemical class | Essential branched-chain α-amino acid — sec-butyl side chain; two chiral centres |
| CAS | 73-32-5 |
| Primary source | Microbial fermentation, typically Corynebacterium glutamicum |
| Key applications | BCAA blends, muscle protein substrate, skeletal muscle glucose uptake research |
| Claim strength | Moderate for glucose uptake in preclinical work; low for isolated supplementation outcomes |
| Typical form | Crystalline powder at 98–99% |
| Buy from Herbuno | L-Isoleucine Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: Isoleucine is the structural isomer of leucine — same molecular formula, different arrangement of the branched side chain. Felix Ehrlich isolated it in 1903 from sugar beet molasses and named it for the relationship. It is unusual among proteinogenic amino acids in having two chiral centres rather than one, which means four stereoisomers exist and only one, L-isoleucine, is biologically active. This makes optical specification more consequential here than for most amino acids.
Discovery and production history: Isoleucine is essential, and metabolically it sits between its two branched-chain relatives: it is both glucogenic and ketogenic, where valine is purely glucogenic and leucine purely ketogenic. Its catabolism yields both acetyl-CoA and succinyl-CoA. Commercial production is by fermentation, and isoleucine is generally the most difficult and expensive of the three branched-chains to produce at high purity, which is reflected in BCAA blend economics.
Research trajectory: Isoleucine has one genuinely distinctive research thread that neither leucine nor valine shares. Work from the 2000s onward, largely in rodent models and cell systems, found isoleucine stimulating glucose uptake into skeletal muscle through a mechanism partly independent of insulin and distinct from leucine's mTOR signalling. This generated interest in isoleucine for glycaemic applications. Separately, more recent work on dietary branched-chain restriction and metabolic health has complicated the picture considerably.
Commercial source: L-isoleucine is produced by fermentation using Corynebacterium glutamicum or related strains and crystallised to 98% or above. Because of the two chiral centres, the production route must deliver the correct stereochemistry at both; allo-isoleucine, the diastereomer, is a meaningful impurity to specify. Substrate determines vegan, non-GMO, kosher and halal eligibility.
Evidence for L-Isoleucine Applications
The glucose uptake finding is isoleucine's one distinctive claim and it remains largely preclinical. Studies in rodents and in cultured muscle cells have shown isoleucine increasing glucose uptake into skeletal muscle and lowering plasma glucose, through mechanisms that appear partly insulin-independent and are not shared by leucine. The effect is reproducible in those systems. Human intervention trials demonstrating meaningful glycaemic benefit from isoleucine supplementation are sparse, and the translation from rodent to human has not been established. Claim strength: Emerging.
Recent metabolic work points in an uncomfortable direction for the category. Studies examining dietary restriction of branched-chain amino acids, and of isoleucine specifically, have reported improvements in metabolic health, insulin sensitivity and in rodent models lifespan. Higher circulating BCAA concentrations are consistently associated with insulin resistance in human cohort data. Whether this is causal or reflects impaired BCAA catabolism as a consequence of insulin resistance is unresolved. Either way, it sits awkwardly alongside marketing that positions BCAAs as metabolically beneficial. Claim strength: Emerging, and in tension with category positioning.
As with valine, there is no substantial standalone supplementation evidence. Isoleucine is studied almost exclusively within BCAA or EAA mixtures, and those designs cannot attribute effects to it. The glucose uptake work is the exception, and it is preclinical. Claims for performance, recovery or body composition from isoleucine specifically are not supported by human trials. Claim strength: Emerging.
The dual glucogenic and ketogenic metabolism is a real distinction with practical consequences in clinical nutrition. Isoleucine catabolism generates both acetyl-CoA and succinyl-CoA, so it can contribute to both ketone body formation and gluconeogenesis depending on metabolic state. This is why the three branched-chains are not metabolically interchangeable despite being blended as though they were, and it is part of the rationale for using mixtures rather than single branched-chains in catabolic illness. Claim strength: High for the biochemistry.
Isoleucine is the cost driver in BCAA blends, which is commercially relevant even though it is not a health claim. It is the most difficult of the three to produce at high purity by fermentation, and its price per kilogram typically exceeds both leucine and valine. This is part of why ratios skewed heavily toward leucine — 8:1:1, 10:1:1 — appeal to manufacturers, and formulators should be aware that an unusual ratio may reflect cost engineering presented as a performance rationale. Claim strength: High.
Maple syrup urine disease applies to isoleucine as to the other two, and alloisoleucine is specifically relevant. In MSUD, branched-chain ketoacid dehydrogenase deficiency causes all three branched-chains to accumulate, and plasma alloisoleucine — the isoleucine diastereomer — is the most specific diagnostic marker for the condition. High-BCAA products are contraindicated. Dietary management requires precise control of all three amino acids. Claim strength: High.
Sourcing L-isoleucine from Herbuno. We supply fermentation-derived L-isoleucine at 98% as a crystalline powder for BCAA and EAA blends and clinical nutrition applications.
Specify allo-isoleucine as an impurity limit — isoleucine has two chiral centres and the diastereomer is the meaningful quality marker here, which a standard assay will not catch. All lots ship with CoA and MSDS as standard; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
Isoleucine is dosed as the free amino acid at 98% or above. In a conventional 2:1:1 BCAA blend it occupies one quarter of the total, so a 5 gram serving delivers 1.25 grams. Adult requirement is around 19 milligrams per kilogram daily, met comfortably by adequate protein intake. There is no established standalone supplemental dose; the preclinical glucose uptake work used doses that do not translate directly to human supplementation.
Ratio decisions in BCAA blends should be made with the cost structure visible. Isoleucine is the most expensive of the three to manufacture, so leucine-skewed ratios reduce cost per serving. There is no comparative trial evidence favouring any ratio, which means a 10:1:1 product is neither supported nor refuted by data — but a formulator should know that the commercial incentive points toward leucine-heavy ratios independent of any performance argument. If a supplier proposes an unusual ratio, ask what it is based on.
Handling is comparable to valine and easier than leucine. Isoleucine dissolves at around 4 grams per 100 millilitres at room temperature, between valine and leucine, and is distinctly bitter in common with the group. It is stable to heat and across a wide pH range, not notably hygroscopic, and compatible with the usual blend components. In ready-to-mix formats the limiting factor remains leucine's poor dispersion rather than isoleucine's, though the cumulative bitterness of all three requires a masking strategy planned at formulation rather than added later.
For analytical control, specify identity and assay by HPLC or ion-exchange chromatography, and require allo-isoleucine as a specified impurity — this is the point that distinguishes a proper isoleucine specification from a generic amino acid one, since the two chiral centres mean a diastereomer can be present without the assay flagging it. Optical rotation should confirm configuration. Standard specifications cover heavy metals, residual solvents, microbiological limits and loss on drying, with the fermentation organism and substrate named for certification purposes.
Supplier qualification warrants more attention for isoleucine than for the other two branched-chains, for two reasons. The production difficulty that makes it the most expensive of the three also makes it the most likely point of substitution or under-declaration in a blend: an analysis of the finished blend against its label ratio, rather than reliance on the component certificates, is the check that catches this. And because branched-chain volume is driven overwhelmingly by animal feed, the specification gap between feed and supplement grade is material — microbiological limits, residual host-cell protein, endotoxin and heavy metals are all controlled more tightly for human-grade material. A price materially below the prevailing supplement-grade range for isoleucine specifically should prompt a question rather than an order.
On positioning, the honest framing for isoleucine is narrower than the category generally allows. The glucose uptake work is genuinely interesting and is the only distinctive mechanistic story among the three branched-chains, but it is preclinical, and the parallel literature associating higher circulating branched-chain concentrations with insulin resistance points the other way. A product positioned on isoleucine's glycaemic mechanism is building on a signal that human trials have not confirmed and that sits in tension with cohort data. For a B2B specification document the defensible statements are the biochemistry — dual glucogenic and ketogenic catabolism, the role in muscle protein as one of nine essentials — and the analytical distinctions, principally allo-isoleucine. Those hold without qualification; the glycaemic story does not yet.
Frequently Asked Questions — L-Isoleucine
What makes isoleucine different from the other BCAAs?
Two things. Metabolically it is both glucogenic and ketogenic, where valine is purely glucogenic and leucine purely ketogenic. And it has its own research thread on skeletal muscle glucose uptake, apparently partly insulin-independent and not shared by leucine. That work is largely rodent and cell-based though — human translation is not established.
Is there a metabolic downside to BCAAs?
There is a live question. Studies restricting branched-chains, and isoleucine specifically, have reported improved insulin sensitivity and metabolic health, and higher circulating BCAA levels are consistently associated with insulin resistance in human cohorts. Whether that is causal or a consequence of impaired catabolism is unresolved. Either way it sits awkwardly with marketing that positions BCAAs as metabolically beneficial.
Why are some BCAA blends 8:1:1 or 10:1:1?
Cost is part of it. Isoleucine is the most expensive of the three to manufacture, so leucine-skewed ratios reduce cost per serving. No comparative trial supports any ratio over another, so an unusual ratio is neither supported nor refuted — but the commercial incentive points toward leucine-heavy independent of any performance argument. Ask what a proposed ratio is based on.
What impurity should I specify?
Allo-isoleucine. Isoleucine has two chiral centres rather than one, so a diastereomer can be present without a standard assay flagging it. This is the point that distinguishes a proper isoleucine specification from a generic amino acid one. Allo-isoleucine is also the most specific plasma marker for maple syrup urine disease.
Does isoleucine help blood sugar?
The preclinical signal is real and reproducible — rodent and cell studies show increased skeletal muscle glucose uptake. Human intervention trials showing meaningful glycaemic benefit from supplementation are sparse. We would call this Emerging and not position a product on it.
Why source isoleucine from India?
Around 80% of raw nutraceutical ingredients originate in China and amino acids are among the most concentrated categories, so a second qualified origin is a continuity measure. Isoleucine is the hardest of the three branched-chains to produce at high purity, so qualifying a second source matters more here than for leucine or valine.